Assenagon Asset Management S.A. Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Assenagon Asset Management S.A. raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 478.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,504 shares of the biopharmaceutical company's stock after buying an additional 41,768 shares during the quarter. Assenagon Asset Management S.A. owned about 0.09% of Agios Pharmaceuticals worth $1,125,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AGIO. Envestnet Asset Management Inc. purchased a new position in Agios Pharmaceuticals during the first quarter valued at $230,000. MetLife Investment Management LLC increased its holdings in shares of Agios Pharmaceuticals by 57.7% during the first quarter. MetLife Investment Management LLC now owns 32,047 shares of the biopharmaceutical company's stock valued at $933,000 after acquiring an additional 11,726 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Agios Pharmaceuticals by 39.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,010,616 shares of the biopharmaceutical company's stock valued at $29,420,000 after acquiring an additional 285,215 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Agios Pharmaceuticals by 10.1% during the first quarter. Allianz Asset Management GmbH now owns 55,620 shares of the biopharmaceutical company's stock valued at $1,619,000 after acquiring an additional 5,120 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,085,814 shares of the biopharmaceutical company's stock valued at $148,048,000 after acquiring an additional 17,224 shares in the last quarter.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded down $0.37 during trading hours on Friday, hitting $27.55. The company's stock had a trading volume of 565,799 shares, compared to its average volume of 534,942. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $35.50. The company's 50 day simple moving average is $28.43 and its two-hundred day simple moving average is $24.69. The company has a market cap of $1.55 billion, a P/E ratio of -4.35 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by ($0.08). The firm had revenue of $7.10 million during the quarter, compared to analysts' expectations of $7.80 million. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company's revenue for the quarter was up 65.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 earnings per share. As a group, research analysts predict that Agios Pharmaceuticals, Inc. will post -5.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider James William Burns sold 1,708 shares of the firm's stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $36,961.12. Following the transaction, the insider now directly owns 30,378 shares of the company's stock, valued at $657,379.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 8,391 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $22.99, for a total value of $192,909.09. Following the sale, the director now owns 116,075 shares of the company's stock, valued at approximately $2,668,564.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James William Burns sold 1,708 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $36,961.12. Following the completion of the sale, the insider now directly owns 30,378 shares in the company, valued at approximately $657,379.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,815 shares of company stock valued at $1,232,699. Insiders own 4.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AGIO. JPMorgan Chase & Co. reduced their price target on Agios Pharmaceuticals from $31.00 to $30.00 and set a "neutral" rating for the company in a report on Friday, February 23rd. Royal Bank of Canada reduced their price objective on Agios Pharmaceuticals from $43.00 to $42.00 and set an "outperform" rating for the company in a report on Friday, February 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $33.50.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.